Modulation and recruitment of TRF2 at viral telomeres during human herpesvirus 6A/B infection

Shella Gilbert-Girard¹, Annie Gravel¹, Vanessa Collin¹, Darren J. Wight², Benedikt B. Kaufer², Eros
Lazzerini-Denchi³ and Louis Flamand^{1,4}

¹Division of Infectious Disease and Immunity, CHU de Québec Research Center, Quebec City, Quebec
Canada, G1V 4G2; ²Institut für Virologie, Freie Universität Berlin, Berlin, Germany; ³Laboratory of
Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
and ⁴Department of microbiology, infectious disease and immunology, Faculty of Medicine, Université
Laval, Quebec City, Québec, Canada, G1V 0A6

To whom correspondence should be addressed:

Louis Flamand PhD MBA

Division of Infectious Disease and Immunity

Room T1-49

CHU de Quebec Research Center,

Quebec City, Canada

G1V 4G2

Tel (418)-525-4444 ext 46164; Fax (418)-654-2765

Email:Louis.flamand@crchul.ulaval.ca

Abstract

Human herpesviruses 6A and 6B (HHV-6A/B) can integrate their genomes into the telomeres of host chromosomes. The HHV-6A/B genomes contain telomeric repeats essential for integration. Whether HHV-6A/B infections impact telomere homeostasis remains to be studied. We report that during infection, a massive increase in telomeric signals is observed. Such telomeric signals are detected in viral replication compartments (VRC) that colocalize with the viral IE2 and P41 proteins. Infection with HHV-6A mutants lacking telomeric repeats did not reproduce this phenotype. HHV-6A/B infections lead to increased expression of three shelterin genes, TRF1, TRF2 and TPP1. TRF2 was recruited to VRC and binding to the HHV-6A/B telomeric repeats demonstrated by chromatin immunoprecipitation and ELISA. Lastly, the HHV-6A IE2 protein colocalized with shelterin proteins at telomeres during infection. In summary, HHV-6A/B infections results in an excess of telomeric repeats that stimulates the expression of shelterin genes. TRF2 binds to viral telomeres during infection and localizes with HHV-6A IE2 protein. Our results highlight a potential role for shelterin complex proteins and IE2 during infection and possibly during integration of HHV-6A/B into host chromosomes.

37

38 **Introduction**

39 Human herpesvirus-6A (HHV-6A) and HHV-6B are two distinct beta herpesviruses with different
40 epidemiological and biological characteristics (1). HHV-6B is a ubiquitous virus that infects nearly
41 100% of world population and is the etiological agent of roseola infantum, an infantile febrile illness
42 characterized by high fever with occasional skin rash (2). HHV-6B is also a concern in hematopoietic
43 stem cell and solid organ transplant recipients with frequent reactivation and medical complications
44 (3). Pathological and epidemiological data on HHV-6A remain scarce.

45 The viral genomes of HHV-6A/B are composed of a unique segment of approximately 143 kbp flanked
46 at both extremities with identical and directly repeated (DR) termini of approximately 9 kbp each.
47 Each DR contains two regions with repeated TTAGGG telomeric sequence that play a role in the ability
48 of these viruses to integrate their genomes into human chromosomes (4) and reviewed in (5, 6). The
49 number of telomeric repeats within each DR ranges from 15 to 180 copies in clinical isolates (7-10).
50 Although HHV-6 integration can occur in several distinct chromosomes, it invariably takes place in the
51 telomeric/sub-telomeric regions of chromosomes (11-14). When integration occurs in a gamete, the
52 viral genome can be inherited resulting in individuals carrying a copy of the viral genome in every cell,
53 a condition called inherited chromosomally integrated HHV-6 (iciHHV-6) (15). Approximately 1% of
54 the world population is considered iciHHV-6⁺ (reviewed in (6)). The consequences of iciHHV-6 are not
55 well defined but a recent study indicates that iciHHV-6⁺ individuals are at greater risks of developing
56 angina pectoris (16).

57

58 The ends of mammalian chromosomes are composed the telomeres consisting in 5kb to 15 kb of
59 telomeric repeats (TTAGGG) followed by a 200 +/- 75 nucleotide TTAGGG single-stranded 3'-overhang

(17). The telomeres function as a buffer zone to avoid instability and loss of genetic information. With each cell division, the extremities of the chromosomes are incompletely replicated due to the end replication problem (18). As a consequence, the telomeres shorten after every cell division until they reach a minimal threshold length, which triggers DNA damage activation via the ATR (ataxia telangiectasia and Rad3 related) or the ATM (ataxia telangiectasia mutated) pathway ultimately leading to apoptosis or senescence (reviewed in (19, 20)). In the absence of telomere elongating processes, such as expression of telomerase or activation of the alternative lengthening of telomere (ALT) pathway, somatic cells are therefore capable of a limited number of replication cycles.

To prevent activation of DNA damage recognition pathways, chromosome ends are protected by binding the shelterin complex at telomeric repeats (19). The shelterin complex folds telomeric DNA into a secondary structure called the T-Loop, preventing the recognition of the telomere extremity as a double-strand break (DSB) (21). The shelterin complex is made of six proteins: TRF1, TRF2, TPP1, RAP1, TIN2 and POT1. TRF1 and TRF2 both form homodimers that bind directly to the double-strand TTAGGG repeats in a sequence-specific manner (22-24). TRF2 represses activation of the ATM pathway (25) and plays an essential role in end-to-end chromosome fusions mediated by the non-homologous end-joining (NHEJ) pathway (26, 27). POT1 binds to the single-strand section of the telomeres and protects the telomeres against activation of the ATR pathway (26, 28-30).

Certain viruses are reported to affect telomeres in different ways. For example, infection by herpes simplex virus type 1 (HSV-1) alters telomere integrity in several ways, including transcriptional activation of TERRA, loss of total telomeric DNA, selective degradation of TPP1, reduction of telomere-bound shelterin and accumulation of DNA damage at telomere (31). Telomere remodeling is presumed to be required for ICP8-nucleation of pre-replication compartment that stimulates HSV-1 replication (31). The Epstein-Barr virus (EBV) LMP1 protein was reported to downmodulate the

expression of TRF1, TRF2 and Pot1 shelterin genes resulting in telomere dysfunction, progression of complex chromosomal rearrangements, and multinuclearity (32, 33). The impact of HHV-6A/B infection of telomere biology is currently unknown. Considering that telomeres are preferred sites for HHV-6A/B integration, it is essential to understand the dynamic processes occurring during the early phases of infection to gain insights into the integration mechanisms. In the present study, we analyzed the impact of HHV-6A/B infections on shelterin complex homeostasis and determined whether its members would associate with viral DNA during infection. We report for the first time that some shelterin proteins expressions are upregulated during HHV-6A/B infection and that TRF2 is recruited to the viral replication compartment and associates with viral DNA during infection.

Materials and Methods

Cell lines and viruses

U2OS cells (American Type culture collection (ATCC), Manassas, VA, USA) were cultured in Dulbecco's modified Eagle's medium (DMEM, Corning Cellgro, Manassas, VA, USA) supplemented with 10% Nu serum (Corning Cellgro), non-essential amino acids (Corning Cellgro), HEPES, sodium pyruvate (Multicell Wisent Inc., St-Bruno, Québec, Canada) and plasmocin 5 µg/ml (InvivoGen, San Diego, CA, USA). HeLa and MCF-7 cells (ATCC) were cultured in the same medium supplemented with 10% fetal bovine serum (FBS) (Thermo Fisher) instead of Nu serum. MOLT-3 (ATCC, CRL-1552), HSB-2 (ATCC, CCL-120.1), both human T lymphoblastic cell lines, were cultured in RPMI-1640 (Corning Cellgro) supplemented with 10% Nu serum (Corning Cellgro), HEPES and plasmocin 5 µg/ml (InvivoGen). J-JHAN cells infected with HHV-6A mutants (Δ TMR and Δ impTMR) (4) were cultured in RPMI-1640 supplemented with 10% FBS. SUP-T1 cells were cultured in RPMI-1640 supplemented with 10% FBS.

105 HHV-6B (Z29 strain) and HHV-6A (GS strain) were propagated on MOLT-3 and HSB-2 cells respectively,
106 as previously described (34).

107 Plasmids

108 IE2 expression vectors (WT and Δ 1290-1500) were previously described (35). pLPC-MYC-hTRF1
109 (Addgene plasmid # 64164) (36) and pLPC-MYC-hPOT1 (Addgene plasmid#12387) (37) were a gift
110 from Titia de Lange and obtained through Addgene. pLKO human shTRF2 was previously described
111 (38). The pSXneo 135(T2AG3) was a gift from Titia de Lange (Addgene plasmid # 12402) (39).

112 Western blots

113 Cells were resuspended in Laemmli buffer and boiled for 5 minutes. Samples were loaded and
114 electrophoresed through a SDS-polyacrylamide gel. Samples were transferred onto PVDF membranes
115 and processed for western blot using rabbit anti-TRF2 (Novus Biologicals), rabbit anti-IE1 (34), and
116 mouse anti-tubulin antibodies (Abcam). Peroxydase-labeled goat anti-rabbit IgG and peroxydase-
117 labeled goat anti-mouse IgG were used as secondary antibodies. The Bio-Rad Clarity ECL reagent was
118 used for detection.

119 IF-FISH and microscopy

120 Immunofluorescence (IF) combined with fluorescence in situ hybridization (FISH) was performed as
121 previously described (40). U2OS cells were seeded at 5×10^4 cells per well in 6-well plates over
122 coverslips, cultured 24 hours and infected with HHV-6A or HHV-6B at a multiplicity of infection (MOI)
123 of 5 for 4 hours. Cells were then washed with PBS and cultured in media for a set period of time. Cells
124 were fixed with 2% paraformaldehyde. HeLa cells were treated the same way but seeded at 3.5×10^4
125 cells per well. MOLT-3 and HSB-2 cells were infected at a MOI of 1 and cultured for a set period of
126 time before being deposited on a 10-well microscope slide, dried and fixed in acetone at -20°C for 10

minutes. The following primary antibody were used: rabbit- α -IE1-Alexa-488 (34), mouse- α -IE2-Alexa-568 (Arsenault et al, 2003, JCV), mouse- α -P41 (NIH AIDS Reagent Program), rabbit- α -TRF2 (NB100-56694, Novus Biologicals), rabbit- α -53BP1 (H-300, Santa Cruz Biotechnology), mouse- α - γ H2AX (Ser139, clone JBW301, EMD Millipore) and mouse- α -PML (PG-M3, Santa Cruz Biotechnology). Secondary antibodies used were goat- α -rabbit-Alexa-488, goat- α -rabbit-Alexa-594, goat- α -mouse-Alexa-488 and goat- α -mouse-Alexa-594 (Life Technologies). FISH was performed using a PNA probe specific to the telomeric sequence (CCCTAA)₃ (TelC-Cy5, PNA BIO).

Slides were observed using a spinning disc confocal microscope (Leica DMI6000B) and analyzed using the Volocity software 5.4.

To compare TRF2 expression in uninfected and HHV-6-infected cells, cells were dually stained with HHV-6 IE2 protein and TRF2. The relative TRF2 fluorescence in IE2- and IE2+ individual cell was then determined using the ImageJ software. TRF2 expression levels were compared using unpaired student t-test with Welch's correction.

Telomere restriction fragment (TRF) analysis.

DNA from uninfected and HHV-6A/B infected cells was isolated using QIAamp DNA blood isolation kits as per the manufacturer's recommendations. Five μ g of DNA were digested overnight with RsaI and HinfI followed by electrophoresis through agarose gel and southern blot hybridization. The telomeric DNA probe was obtained following digestion of the pSXneo 135(T2AG3) vector with EcoRI and NotI, gel purification of the 820 bp fragment and ³²P-labeling by nick translation. After hybridization and washes, the membrane was exposed to X-ray films.

147

148 RNA isolation and RT-qPCR

149 HSB-2 and MOLT-3 cells (10^7 cells) were incubated in a 50 mL tube and infected with HHV-6A or HHV-
150 6B at a MOI of 0,25. After 4h at 37°C, cells were washed and placed in a 25 cm² culture flask at 500
151 000 cells per ml in complete media. A portion of the cells were harvested on day 1, 2, 3, 5 and 7 post-
152 infection. Total RNA was isolated and processed by reverse transcriptase quantitative PCR (RT-QPCR)
153 as previously described (41). The cDNAs obtained were analyzed by TaqMan qPCR using Rotor-Gene Q
154 apparatus (Qiagen) and Rotor-Gene Multiplex PCR Kit reagent (Qiagen) using validated HHV-6-IE1-
155 and GAPDH-specific primers and probes (41). cDNAs were analyzed for TRF1, TIN2, TPP1 using specific
156 primers and SyBr green as described (42). TRF2, POT1, RAP1 were analyzed using the following
157 primers:

158 TRF2 FWD: 5'-GTACCCAAAGGCAAGTGGAA-3' TRF2 REV: 5'-TGACCCACTCGCTTTCTTCT-3'
159 POT1 FWD: 5'-TGAAGTTCTTTAAGCCCCCA-3' POT1 REV: 5'-AGCCTGTGAAAGCGAACAAT-3'
160 RAP1 FWD: 5'-GCCACCCGGGAGTTTGA-3' RAP1 REV: 5'-GGGTGGATCATCATCACATAGT-3'

161 The C_t value of genes from infected cells was compared to the value of uninfected cells and
162 normalized with the GAPDH cellular gene.

163 Flow cytometry

164 HSB-2 cells were mock-treated or infected with HHV-6A (U1102) at a MOI of 0.5. After 48 hours, 1 x
165 10⁶ cells/assay were fixed, permeabilized and processed for detection of HHV-6 antigens (p41
166 (9A5D12 from NIH AIDS Reagent Program) and gp102 (7A2 from NIH AIDS Reagent Program)) and
167 TRF2 (Novus Biologicals) using the intracellular fixation and permeabilization buffer kit (eBiosciences,
168 San Diego, CA, USA). One µg of antibody was used per assay. Cells were analyzed by flow cytometry
169 using a FACS scan apparatus and CellQuest software.

170 ChIP and dot blot

171 The experiments were made using the Pierce Magnetic ChIP Kit (Thermo Scientific) according to the
 172 manufacturer's instructions with a few modifications. Equal quantities of HSB-2 and MOLT-3 cells
 173 were used for all samples (4×10^6 cells/sample). Cross-linking lasted 10 minutes at RT. Two μ L of
 174 diluted MNase (1:10) were added to each sample for MNase digestion. Before sonication, an aliquot
 175 was saved for normalization purpose (input). Sonication was made with a Branson Sonifier 450, with
 176 an Output Control set at 1. Each sample was sonicated with five pulses of 20 seconds, each pulse
 177 followed by a 20 seconds incubation on ice. Before immunoprecipitation, samples were incubated
 178 with magnetic beads alone for one hour at 4°C before discarding the beads. The immunoprecipitation
 179 was performed using 2 μ L of normal rabbit IgG (negative control) and 4 μ g of rabbit anti-TRF2
 180 antibody (NB100-56694, Novus Biologicals) with an overnight incubation at 4°C. Protein A agarose
 181 beads were added for 1h at 4°C followed by three washes. The DNA was eluted in 50 μ L of DNA
 182 column elution solution.

183 Eluted DNA was analyzed by dot blot hybridization using telomeric probe ((CCCTTA)₄ probe) or HHV-6
 184 probe (DR6) while the input was analyzed using an Alu probe. The DNA was first denatured for 10
 185 minutes at room temperature in 0.25 N NaOH and 0.5 M NaCl. Samples were then serially diluted in
 186 0.1 X SSC and 0.125 N NaOH, on ice, loaded onto nylon membrane, neutralized in 0.5 M NaCl and 0.5
 187 M Tris-HCl pH 7.5 and crosslinked using UV irradiation. Membranes were pre-incubated in Perfecthyb
 188 Plus hybridization buffer (Sigma-Aldrich) for 2h at 60°C before addition of 1×10^6 CPM/ml of ³²P-
 189 labeled probes. Hybridization was carried out for 16h at 60°C. Membrane was washed twice with 2X
 190 SSC-1% SDS, twice with 1X SSC-1% SDS and once with 0.5X SSC-1% SDS at 60°C, for 15 minutes each.
 191 Membrane was then exposed to X-ray films at -80°C.

192 Cloning and purification of MBP-TRF2.

193 The pLPC-NMYC TRF2 was a gift from Titia de Lange (Addgene plasmid # 16066). The TRF2 coding
194 sequence was excised from pLPC-NMYC TRF2 vector using with BamHI and XhoI and cloned in frame
195 with the MBP coding sequence of the pMAL-C2 vector (New England Biolabs) using BamHI and Sall
196 enzymes. MBP and MBP-TRF2 proteins were expressed in BL21 DE3 RIL bacteria and purified by
197 affinity chromatography, as described (43).

198 Electrophoretic mobility shift assay (EMSA).

199 EMSA was performed essentially as described (43). In brief, recombinant proteins (MBP and MBP-
200 TRF2) were incubated with double-stranded (ds) non-telomeric or telomeric labeled probes in 20 µl of
201 the following reaction buffer: 20 mM Hepes-KOH pH 7.9, 150 mM KCl, 1 mM MgCl₂, 0.1 mM EDTA, 0.5
202 mM DTT, 5% glycerol and 0.1 mg/ml BSA. For competition experiments, 10-1000 fold excess
203 unlabeled ds non-telo or telomeric probes were included in the reaction buffer. After a 30 minute
204 incubation at room temperature, 2 µl of loading dye were added and the samples were
205 electrophoresed through a non-denaturing 5% acrylamide:bis (29:1) gel. After migration, the gels
206 were dried and exposed to X-ray films at -80°C.

207 Detection of TRF2 binding to HHV-6 telomeric sequence

208 The wells of a 96-well ELISA plate were coated with 25 ng MBP or 50 ng of MBP-TRF2 proteins by
209 overnight incubation at 4°C in pH 9.0 carbonate buffer. After rinsing, 1% BSA was added to block non-
210 specific sites. Twenty-five nanograms of HaeIII-digested digoxigenin-labeled HHV-6A DNA (HaeIII cuts
211 the viral genome 289 times) in EMSA reaction buffer were added. For competition experiments, 2.5 or
212 5.0 pmoles of non-telomeric or telomeric dsDNA were added 15 minutes prior to the addition of HHV-
213 6A DNA. The plate was incubated for 2h at room temperature (RT). After 3 washes with TBS-0.1%
214 Tween-20 (TBS-T), peroxidase-labeled mouse anti-DIG antibodies were added to each well for 1h at

RT. After 3 additional TBS-T washes, TMB substrate was added and the reaction allowed to develop for 15 minutes before addition of 50µl of 2N sulfuric acid. Absorbance was measured at 450 nm.

Results

Telomeric sequence accumulation during HHV-6A infection.

Telomeres help protect against the loss of genetic information due the linear DNA end replication problems encountered during each cell division. Telomeric repeats are the binding sites of six proteins referred to as the shelterin complex that prevent induction of a DDR at chromosome ends. Interestingly, the extremities of the HHV-6A/B genomes also contain stretches of telomeric (TTAGGG)_n repeats that vary in number between 15 and 180 (7-10) (Figure 1A). Using fluorescent *in situ* hybridization (FISH), we first studied the accumulation of telomeric sequences during active HHV-6A infection. Hybridization of mock-infected HSB-2 cells with a telomeric probe resulted in the detection of many discrete punctate telomeric signals corresponding to chromosome telomeres (Figure 1B). In contrast, a mixture of small and enlarged telomeric signals were observed during HHV-6A infection. At late stages of infection when viral genome replication is abundant, very intense telomeric signals were detected. These telomeric signals likely correspond to replicating virus genomes as they localize with the IE2 protein that is presumed to associate with viral DNA (44) (Figure 1B, bottom panels). Similar results were observed in HHV-6B-infected cells (Figure 1C). Using ddPCR we have quantified the number of viral DNA copies/cell at 96h post-infection and assuming all cells are productively-infected, results indicate that between 15,000 and 18,000 viral DNA molecules/per cell are present during active infection. Considering that 116 and 80 TTAGGG repeats/genome are respectively present in HHV-6A and HHV-6B (7), between 750 000 and 2 million telomeric repeats are present in HHV-6A/B-infected cells compared to 125 000 telomeric repeats in uninfected cells (assuming 8kbp/telomere) (Figure 1D). Such increase in telomeric signals was also

monitored by terminal restriction fragment (TRF) analysis. As shown in figure 1E, uninfected cells displayed telomeres lengths ≥ 2 kbp. In addition to the cellular telomeric signal observed, HHV-6A/B infected cells displayed abundant signals that were smaller in size (< 2 kbp) and with much stronger intensity, representing viral telomeric signals.

The accumulation of telomeric sequences was confirmed using J-JHAN cells infected with a recombinant HHV-6A. As with HSB-2 cells, mock-infected J-JHAN showed typical telomeric staining (Figure 1F, first row). J-JHAN cells productively infected with HHV6-A demonstrated large telomeric signals that colocalized with the viral IE2 protein (second row). To demonstrate that the increase telomeric signals observed originates from viral DNA, we made use of HHV-6A mutants lacking either only the imperfect telomeric repeats (Δ impTMR) or all telomeric repeats (Δ TMR) (4). Infection with the Δ impTMR mutant still resulted in a strong and patchy telomeric signals (Figure 1F, third row). In contrast, telomeric hybridization signals in Δ TMR-infected J-JHAN cells were similar to those observed in uninfected J-JHAN cells (Figure 1F last row), confirming that telomeric sequences within the viral genome were responsible for the increased telomeric signals observed.

Modulation of the shelterin complex expression during HHV-6A/B infection.

Telomeres are bound by a series of 6 proteins referred to as the shelterin complex. Considering the increase in telomeric sequences detected during active HHV-6A/B infections, we surmised that shelterin expression is likely to be modulated during infection. Total RNA was isolated at varying time points post HHV-6A/B infections and RT-qPCR was performed using primers specific for each of the shelterin genes as well as the telomerase gene. The cellular *GAPDH* gene was used for normalization. As showed in figures 2A-F, HHV-6A infection of HSB-2 cells led to increased expression of TRF1, TRF2, RAP1 and TPP1 mRNAs with statistical significance ($p < 0.05$) observed on day 7 post-infection.

261 Variations in POT1, and TIN2 mRNA levels were only minimal. Similarly, HHV-6B infection of MOLT-3
262 cells caused a significant increase in TRF2 and TPP1 mRNAs levels relative to uninfected control cells
263 (Figures 2H-M). Other shelterin genes were not significantly modulated. HHV-6 infection was
264 monitored by assessing U90 gene expression (Figure 2G).

265 We next investigated whether these changes in shelterin mRNA levels would translate in increased
266 protein expression. We infected HSB-2 cells with HHV-6A and analysed intranuclear TRF2 expression
267 by flow cytometry. HHV-6A-infected cells were identified by detection of P41 or gp102 viral proteins
268 expression. The mean TRF2 fluorescence intensity (MFI) in uninfected cells varied between 261 and
269 210 (Figures 3A-B). In HHV-6A-infected cells, two cell populations were observed. Infected ones,
270 expressing P41 or gp102, and uninfected bystander cells. As shown, HHV-6A-infected cells expressed
271 TRF2 at higher levels (MFI of 385 and 376) relative to uninfected cells within the same population
272 (MFI of 204 and 259). Similar results were obtained in HHV-6B-infected Molt3 cells with a MFI TRF2 of
273 314 in infected cells relative to MFI TRF2 of 180 and 117 in uninfected or p41⁻ cells, respectively
274 (Figure 3C).

275 TRF2 expression levels in mock-infected and HHV-6A/B infected cells was also assessed by western
276 blot analysis. As shown in figure 3D, compared to mock-infected cells, HHV-6A and HHV-6B-infected
277 cells had TRF2 protein expression levels that were increased 1.3X and 1.8X, respectively. These
278 results (Figures 3A-D) confirm the mRNA data and indicate that TRF2 is expressed at higher levels in
279 HHV-6A/B-infected cells.

280 T cell lines such as HSB-2 and Molt3 are highly susceptible to HHV-6 replication and typically used for
281 HHV-6 propagation. As most cells are lytically infected and subsequently killed, HHV-6A/B integration
282 in such cells does not occur frequently. We therefore determined whether TRF2 expression would

283 also be modulated in semi-permissive cells, such as U2OS that we and others routinely use to study
 284 HHV-6A/B integration (45). TRF2 expression in HHV-6A-infected U2OS cells was measured using
 285 confocal microscopy. After 24h, 48h and 72h post-infection, individual cells were analyzed for TRF2
 286 expression. Infected cells were distinguished from uninfected bystander cells using the anti-IE2
 287 antibody (Figure 4A). Fluorescence was quantified using ImageJ software (Figure 4B). The results
 288 obtained indicate that starting at 24h post-HHV-6A infection, TRF2 is expressed at significantly higher
 289 levels in infected cells than bystanders or uninfected cells ($p \leq 0.02$). No significant difference in TRF2
 290 expression was detected between bystander and mock-treated cells. In summary, these results
 291 indicate that expression of TRF2 increases during HHV-6A/B-infections.

292 **Binding of TRF2 to viral telomeric sequences**

293 Telomeres are protected by the shelterin complex of which TRF1 and TRF2 bind directly to TTAGGG
 294 repeats; however, it remains unknown if shelterin proteins bind to viral telomeric sequences in the
 295 context of the HHV-6A/B genomes. To study TRF2 binding to viral TMRs, a recombinant MBP-TRF2
 296 protein was generated. To validate that MBP-TRF2 was functional and capable of binding telomeric
 297 DNA, we performed EMSA. MBP-TRF2 efficiently bound dsDNA with telomeric sequences causing a
 298 mobility shift (figure 5A). MBP alone did not bind the telomeric probe. The specificity of MBP-TRF2
 299 binding was confirmed by a competition with excess unlabeled telomeric and non-telomeric
 300 oligonucleotides. Excess (100-1000 fold) of unlabeled telomeric oligonucleotides efficiently competed
 301 with labeled telomeric probes. No such competition was observed with excess non-telomeric
 302 oligonucleotides. Lastly, no binding of MBP or MBP-TRF2 was observed using non-telomeric labeled
 303 probes (Figure 5B).

304 After validation of the specific binding to telomere sequences of the recombinant MBP-TRF2 protein,
 305 we next determined if MBP-TRF2 is able to bind to HHV-6 TMR DNA. To study this, DIG-labeled HHV-
 306 6A-BAC DNA was digested with the HaeIII enzyme that cuts on both sides of the viral TMR and more
 307 than 250 times in the viral genome. MBP and MBP-TRF2 coated plates were incubated with the
 308 mixtures of DNA fragments (25 ng) and DNA binding was measured using anti-DIG antibodies. MBP
 309 did not bind viral DNA, in contrast to MBP-TRF2 that efficiently bound viral DNA (Figure 5C).
 310 Specificity of MBP-TRF2 binding to viral TMR was confirmed through successful competition with
 311 unlabeled ds oligonucleotides containing telomeric motifs (Telo comp) but not by ds oligonucleotides
 312 with non telomeric motifs (non Telo comp). Our *in vitro* binding assay revealed that the recombinant
 313 MBP-TRF2 efficiently binds to viral DNA at TMR.

314 To validate these results, colocalization of TRF2 with viral DNA during infection was studied next. As
 315 reported previously (45), HHV-6A/B infection of U2OS is abortive in most cells with little or no viral
 316 DNA replication observed. In such cells, the HHV-6A IE2 protein was dispersed throughout the nucleus
 317 in several independent foci (Figure 4). However, in a minority of cells, IE2 displays a patchy
 318 appearance reminiscent of viral replication compartments (VRC) (Figure 6A). The presence of IE2 to
 319 VRC was confirmed by co-staining cells for the HHV-6 DNA processivity factor P41 that is known to
 320 associate with the viral DNA polymerase (46, 47). P41 and IE2 associated with large diffuse telomeric
 321 signals that represent viral TMRs (Figure 6A). Colocalization of TRF2 at VRC was studied next. As
 322 shown in figure 6B, in HHV-6A-infected U2OS cells with VRC, TRF2 colocalized with IE2 along with
 323 diffuse telomeric signals. In infected cells where VRC were not detected (most cells), the presence of
 324 diffuse telomeric signals and “patchy” IE2 was not observed (Figure 6B, last row). Despite the absence
 325 of VRC, TRF2 and IE2 often colocalized during infection. To determine if ectopically-expressed IE2
 326 would colocalize to telomeres and TRF2 in the absence of other viral proteins or viral DNA, U2OS were

transfected with an empty vector or an IE2 expression vector and cells were analyzed by IF-FISH. IE2 displayed a punctate nuclear distribution, with while most of IE2 colocalized with endogenous TRF2 (Figure 6C). Whether IE2 requires its C-terminal DNA-binding domain (DBD) for telomeric localization was studied next. Cells expressing an IE2 mutant lacking the DBD mutant was found to localize at telomeres as efficiently as WT IE2 (figure 6D).

We next investigated if HHV-6A IE2 protein would colocalize with other shelterin proteins during infection. U2OS were transfected with myc-tagged TRF1 and POT1 expression vectors, infected with HHV-6A and analyzed by IF-FISH. Both TRF1 and POT1 colocalized with telomeres in control cells as expected (Figures 6E-F). In HHV-6A-infected cells, IE2 was found to partially colocalize with both TRF1 and POT1 at telomeres.

So far, the results obtained indicate that IE2 colocalizes with shelterin complex at telomeres. In addition, TRF2 colocalizes with VRC during infection, suggesting that telomeric sequences within HHV-6 DNA are likely recognized and bound by TRF2. To provide additional support to this hypothesis, we performed TRF2 ChIP in HHV-6A and HHV-6B productively-infected cells. Uninfected cells were used as negative controls. Using equal amounts of starting material, DNA-bound by TRF2 was immunoprecipitated (IP) using anti-TRF2 antibodies and the DNA analyzed by dot blot hybridization. TRF2 efficiently bound telomeric sequences in both uninfected and HHV-6A- and HHV-6B-infected cells (Figures 7B-E). In addition, a stronger telomeric signal was observed in infected cells relative to uninfected cells. To discriminate between telomeres of cellular and viral origin, the TRF2 immunoprecipitated DNA was hybridized with the DR6 probe, corresponding to regions adjacent (1.5kbp) to the TMR in the virus genome (refer to Figure 7A). As shown, the DR6 probe preferentially bound to DNA isolated from HHV-6-infected cells (Figures 7B-E). As negative control, DNA was immunoprecipitated with an irrelevant mouse anti-IgG. As positive control, DNA was IP using anti-

350 RNA PolIII antibodies and analyzed by qPCR for GAPDH promoter DNA (not shown). These results
351 indicated that during infection, HHV-6A and HHV-6B TMRs are physically bound by TRF2.
352 In summary, these assays provide evidence that TRF2 binds the telomeric motifs present in HHV-6A/B
353 DNA.

354 **TRF2 is not required for IE2 localization at viral replication compartment.**

355 Considering that HHV-6A IE2 colocalizes with TRF2 at cellular telomeres (Figures 6B-C) and with TRF2
356 at VRC (Figure 6B), we hypothesized that TRF2 might influence IE2 localization. We generated an
357 U2OS cell line carrying a doxycycline (Dox)-inducible shRNA targeting TRF2 mRNA. Incubation of cells
358 with Dox for 7 days resulted in TRF2 knockdown (Figure 8A). In the absence of Dox, TRF2 and IE2 were
359 found to localize at VRC following HHV-6A infection (Figure 8B, top row). Upon TRF2 knockdown, IE2
360 still localized efficiently to VRC, indicating that TRF2 is dispensable for IE2 localization at VRC. To
361 confirm that TRF2 knockdown was sufficient to induce a phenotype, the DDR at telomeres was
362 assessed. Cells expressing TRF2 (-DOX) expressed little or no phospho 53BP1, a DDR marker (Figure
363 8C). In contrast, mock-infected and HHV-6A-infected cells in which TRF2 knockdown was induced
364 (+DOX) showed robust 53BP1 expression at telomeres, suggesting that TRF2 expression was below
365 the levels required to maintain telomere protection (Figure 8C).

366

367 **Importance of TRF2 during productive viral infection.**

368 Considering that TRF2 colocalize and interacts with viral DNA during HHV-6A/B infections, we
369 determined if TRF2 knockdown would affect HHV-6A/B DNA replications. SUP-T1 cells, susceptible to
370 both HHV-6A and HHV-6B infections, were transduced with a Dox-inducible shTRF2 encoding lentiviral
371 vector. After selection, cells were treated or not with Dox for 20 days after which TRF2 expression

levels were monitored by western blots. TRF2 expression was significantly reduced after 20 days of Dox (Figure 9A). Control (-Dox) and TRF2 KD SUP-T1 cells (+Dox) were infected with HHV-6A or HHV-6B. Infections were allowed to proceed, and intracellular DNA collected at varying time points and analyzed by ddPCR to assess HHV-6A/B DNA copies. The relative quantity of viral DNA was very similar between cells having normal or reduced TRF2 levels (Figures 9B-C), suggesting that TRF2 depletion had only marginal effects on HHV-6A/B DNA replication.

Discussion

Telomeres serve to protect chromosomes from the loss of genetic information. Each chromosome contains several hundreds, even thousands, of tandemly repeated TTAGGG hexamers. Each time a cell divides approximately 150 nucleotides are lost due the end replication problem (48). When telomeres get short, these are extended either by the telomerase enzyme complex (49) or alternative lengthening mechanisms (50, 51). On the other hand, when telomeres get excessively long, proteins such as TAP, can trim the excess telomeres (52). Mechanisms sensing the length of telomeres are therefore present in cells to control telomere length. In the present study, we report that during HHV-6A/B infection, the number of TTAGGG repeats increases significantly (Figures 1B-C). The increase in telomeric sequences originates from the viral genomes that contain between 15 and 180 TTAGGG repeats at each viral extremity (7-10). A HHV-6A mutant lacking these telomeric sequences does not reproduce this phenotype. Using ddPCR we calculated the number of viral DNA molecules to be in excess of 10,000 per cell resulting in an increase in telomeric repeats, in a productively-infected cell, that is 6 to 16 times higher than that of an uninfected cell. The cells responded to this increase in telomeric sequences by turning on TRF1, TRF2, TPP1 and RAP1 genes expression. No increase in POT1

394 or TIN2 was observed. The lack of POT1 induction does not come as a surprise considering that POT1
395 binds to single-stranded telomeric motifs and no such ssDNA is generated by the viral DNA during
396 infection. At the protein level, TRF2 overexpression in HHV-6A/B infected cells was demonstrated by
397 IFA and FACS. The fact that TRF2 upregulation was observed only in HHV-6A/B infected cells indicates
398 a direct consequence of infection rather than potential paracrine effects. TRF2 was found to localize
399 at viral replication compartments along with the HHV-6A IE2 and P41 proteins, the latter being a viral
400 DNA polymerase processivity factor (47). The IE2 protein is a large nuclear protein (circa 1500 amino
401 acids) that behaves as a promiscuous transactivator in gene reporter assays (35, 44). We have
402 previously reported that truncation of the C-terminus abolishes IE2's transactivating potential (35).
403 Recently, the crystal structure of the IE2 C-terminus revealed that it contains dimerization, DNA-
404 binding and transcription factor binding domains explaining the importance of this region for IE2's
405 functions (53). Although IE2 localizes at VRC during infection, whether it binds viral DNA *per se*
406 remains to be demonstrated. Considering that IE2 localizes at HHV-6A Δ TMR VRC, suggests that IE2
407 does not preferentially bind telomeric DNA repeats. Furthermore, considering that in the absence of
408 viral DNA IE2 localizes at cellular telomeres suggest a potential affinity for certain shelterin complex
409 proteins. Of interest, the IE2 C-terminus core structure resembles those of the gammaherpesvirus
410 factors EBNA1 of Epstein-Barr virus (EBV) and LANA of Kaposi sarcoma-associated herpesvirus (KSHV)
411 (53), involved in binding to viral DNA (54, 55). Deletion of the IE2 DNA binding domain had no impact
412 on IE2 localization at telomeres (Figure 6D), further strengthening the hypothesis the IE2 interacts
413 with telomere binding proteins.

414 Using ChIP, we could demonstrate that TRF2 associates with viral DNA during infection. Furthermore,
415 using recombinant TRF2 and BAC viral DNA, we could show that TRF2 binds to viral DNA in the
416 absence of other factors. Binding could be efficiently competed with dsDNA containing telomeric

417 repeats indicating TRF2 binding to viral telomeric sequences. By being attracted to HHV-6A/B TMRs,
 418 TRF2 may leave telomeres unprotected, leading to instability or damage repair. The increase in TRF2
 419 production by the infected cell may compensate for the potential reduction of TRF2 at cellular
 420 telomeres. Alternatively, infected cells may respond to the presence of numerous viral TMRs present
 421 by turning on *TRF2* gene expression, which is supported by our data. Furthermore, the lack of
 422 noticeable DDR at telomeres (data not shown) during infection argues in favor of the latter
 423 explanation.

424
 425 Shelterin protein binding to DNA of other viruses has been reported previously. Binding of TRF2, TRF1
 426 and Rap1 to EBV *oriP*, that contains three TTAGGGTTA motifs, was reported to modulate EBV DNA
 427 replication. TRF2 also interacts with EBNA1, an EBV protein essential for episomal maintenance and
 428 replication (56). While TRF2 and Rap1 promote the replication at *oriP*, TRF1 inhibits it (56-58). TRF2,
 429 together with KSHV LANA protein bind to the latent origin of replication. Such region does not contain
 430 the TTAGGG motif and binding to this region of the viral DNA likely involves a yet to be identified
 431 protein (59). Unlike EBV, the expression of a dominant negative TRF2 does not affect KSHV DNA
 432 replication. In that regard, our results indicating that TRF2 silencing had no impact on HHV-6A/B DNA
 433 replication are similar to those of Hu et al (59).

434 During infection, many viruses provoke a DNA damage response, either because their unprotected
 435 genome is recognized as damaged DNA or because of viral proteins triggering a damage signal. While
 436 several viruses have ways to evade the DDR pathways, some have developed strategies to make use
 437 of the cellular DNA repair proteins to their advantage. Cellular DNA repair proteins have been
 438 observed in viral replication compartment in various cases and can be helpful or even necessary for
 439 completion of the infection (60). During Epstein-Barr virus (EBV) infection, the proteins involved in the

440 ATM pathway checkpoint and HR repair are found in replication compartments (61). The use of the
 441 DDR machinery by EBV likely increases the possibility of molecular events, stimulating the damage
 442 signals causing instability and promoting carcinogenic transformations. Whether viruses can use the
 443 DDR proteins in chromosomal integration is controversial, but some studies have suggested it (60).
 444 One example is the Adeno-associated virus (AAV) that uses the cellular NHEJ mechanism for its site-
 445 specific integration (62). HHV-6A/B chromosomal integration is not fully understood but it appears
 446 probable that these viruses integrate by HR between the virus' TMRs and the cellular telomeres. The
 447 integration occurs solely in telomeres and it has been shown that the telomeric sequences within the
 448 HHV-6A genome are essentials for efficient integration into chromosomes (4). Furthermore, the
 449 integrated virus has been sequenced and its orientation and missing sections are compatible with an
 450 integration by HR between the viral TMRs and the telomeres (11, 63, 64). Whether TRF2 plays a role
 451 in HHV-6A/B integrations remains to be shown. Considering the importance of TRF2 in maintaining
 452 telomere integrity, it is very challenging to demonstrate its role in integration as our current *in vitro*
 453 assays typically require culturing of the cells for a month (45). Depletion of TRF2 for extended times
 454 results in chromosome fusions and subsequent cell death, preventing us from conducting such
 455 experiments.

456
 457 In summary, we showed that during HHV-6A/B infection, the number of telomeric repeats increases
 458 significantly. Such an excess of unprotected telomeric repeats stimulates the expression of shelterin
 459 genes. The shelterin protein TRF2 binds to viral telomeres during infection and localize with HHV-6A
 460 IE2 protein at viral replication compartments. Our results highlight a potential role for shelterin
 461 complex proteins and IE2 during infection and possibly during integration of HHV-6A/B into host
 462 chromosomes.

463 **ACKNOWLEDGMENTS.**

464 We acknowledge the Bioimaging platform of the Infectious Disease Research Centre, funded by an
 465 equipment and infrastructure grant from the Canadian Foundation Innovation (CFI). This work was
 466 funded by a Canadian Institutes of Health Research grants (MOP_123214 and PJT_156118) awarded
 467 to LF. SGG and VC are recipients of fellowships from the Fonds de Recherche Québec-Santé.

468

469 **AUTHOR CONTRIBUTIONS**

470 Conceived experiments: S.G.G. and L.F. Performed experiments: S.G.G., A.G., VC, L.F. Contribution of
 471 key reagents and methodology: B.B.K., D.J.W., E.L.D. Data analysis: A.G., S.G.G., and L.F., Writing :
 472 S.G.G. and L.F. Manuscript revision: S.G.G., A.G., B.B.K., E.L.D., D.J.W., V.C., L.F.

473

474 Figure legends

475 Figure 1: Accumulation of viral telomeric signals during HHV-6A infection. A) Schematic
476 representation of the HHV-6A/B genome. The unique (U) region of the HHV-6A/B genome (140 kbp) is
477 flanked by two direct repeat sequences (10-13 kbp) referred to as DR_L and DR_R. The DRs contain
478 perfect (CCCTAA)_n and imperfect (het(CCCTAA)_n telomeric sequences. The genome is not drawn to
479 scale. B) HSB-2 cells were infected with HHV-6A. After 5 days of infection, cells were processed for IF-
480 FISH to detect HHV-6A IE2 protein (red) and telomeres (cyan) using a telomeric probe. Nuclei were
481 stained with DAPI. C) J-JHAN cells were infected with a recombinant HHV-6A or mutants lacking the
482 imperfect telomeric repeats (Δ impTMR) or lacking all telomeric repeats (Δ TMR). After several days of
483 infection, cells were processed for IF-FISH to detect HHV-6A IE2 protein and telomeres (cyan). Nuclei
484 were stained with DAPI.

485

486 Figure 2: Kinetics of shelterin genes expression during HHV-6A/B infection. HSB-2 cells (A-G) and
487 Molt3 cells (H-M) were respectively infected with HHV-6A or HHV-6B. At various time post infection,
488 total RNA was extracted and analyzed by reverse transcriptase QPCR for *TRF1*, *TRF2*, *POT1*, *RAP1*,
489 *TIN2*, *TPP1*, *GAPDH* and *U90* genes expression. Shelterin genes expression was normalized relative to
490 *GAPDH* gene expression while U90 was analyzed to demonstrate infection. Results represent data
491 from 4-6 independent experiments expressed as mean $\pm$ SD gene expression relative to that of
492 uninfected cells. *p<0.05.

493

494 Figure 3: TRF2 expression during productive HHV-6A/B infections. Mock, HHV-6A- or HHV-6B-infected
495 cells were analyzed for TRF2 expression by flow cytometry. Uninfected and 5 days old HHV-6A-

infected HSB-2 cells (A-B) and HHV-6B-infected Molt3 cells (C) were fixed, permeabilized and stained for TRF2, P41 and gp102 proteins expression. Numbers in the top and bottom left quadrants indicate mean relative TRF2 fluorescence intensities. Results are representative of two independent experiments. D) Western blot analysis of TRF2 expression in HHV-6A/B infected. Tubulin was used as loading controls and IE1 to demonstrate HHV-6A/B infection. Numbers represent TRF2 expression levels relative to mock-infected cells after normalization with tubulin.

Figure 4. Increased TRF2 expression in HHV-6A-infected U2OS cells. U2OS cells were infected with HHV-6A and analyzed for TRF2 and IE2 expression at 24h, 48h and 72h post-infection by dual color immunofluorescence. A) Representative TRF2 and IE2 expression in bystander and IE2 expressing cells at 48h post infection. B) Mean relative TRF2 expression $\pm$ SD in uninfected (white), IE2- (green-uninfected bystander) or IE2+ (red-infected) cells at 24h, 48h and 72h post infection. Each symbol represents the relative TRF2 expression from a single cell.

Figure 5: Binding of TRF2 to HHV-6 viral DNA. Recombinant MBP or MBP-TRF2 were incubated with ³²P-labeled telomeric dsDNA (A) and binding was assessed by EMSA. Excess of unlabeled telomeric and non-telomeric dsDNA were added as competitors. Samples were migrated on non-denaturing acrylamide gel, dried and exposed to X-ray films. B) Recombinant MBP or MBP-TRF2 were incubated with ³²P-labeled non-telomeric dsDNA and binding was assessed by EMSA. C) Recombinant MBP and MBP-TRF2 were coated to the wells of a 96 well-plate and incubated with *HaeIII* digested DIG-labeled HHV-6A DNA (25 ng/condition) in the presence or absence of competitors. After washing, bound DNA was quantified by adding peroxidase-labeled anti-DIG antibodies and substrate. Results are expressed

518 as mean absorbance +SD of triplicate values. Experiment is representative of two additional
519 experiments. *** P<0.001.

520

521 Figure 6. Colocalization of shelterin complex proteins and HHV-6A IE2 protein at viral and cellular
522 telomeres. A) U2OS cells were infected for 48h with HHV-6A after which cells were processed for IF-
523 FISH. Telomeres were labeled in blue, p41 in green and IE2 in red. These images demonstrate
524 colocalization of IE2 with P41, a viral protein that associates with viral DNA during infection, and
525 diffuse telomeric signals (arrows). B) Telomeres were labeled in magenta, TRF2 in green and IE2 in
526 red. The panels in the middle row show images of cells productively infected (minority of cells) with
527 HHV-6A. Large diffuse telomeric signals (viral replication compartments) where TRF2 and IE2
528 accumulates (rectangles) are represented. The panels in the third row represent infected cells that do
529 not actively replicate viral DNA with TRF2 and IE2 colocalizing (dashed squares) at distinct telomeres.
530 C) Colocalization of HHV-6A IE2 protein at telomeres in the absence of viral DNA. U2OS cells were
531 transfected with an empty vector or an IE2 expression vector. Forty-eight hours later cells were
532 processed for dual color immunofluorescence. TRF2 was labeled in green and IE2 in red. Examples of
533 IE2 colocalizing with TRF2 are presented (dashed squares). D) U2OS cells were transfected with WT
534 IE2 or IE2 Δ 1290-1500 expression vectors. Forty-eight hours later cells were processed for IF-FISH.
535 Telomeres were labeled in cyan, IE2 in red and nuclei in blue. Examples of IE2 colocalizing with TRF2
536 are presented (dashed squares). E) Uninfected and HHV-6A-infected U2OS cells were transfected
537 with an empty vector or a myc tagged TRF1 expression vector. Forty-eight hours later cells were
538 processed for IF-FISH. Telomeres were labeled in cyan, TRF1 in green and IE2 in red. Examples of TRF1
539 localizing at telomeres (dashed squares) in uninfected cells are shown in the top row. Examples of IE2
540 colocalizing with TRF1 and telomeres in infected cells are presented in the bottom row (dashed

541 squares). F) Uninfected and HHV-6A-infected U2OS cells were transfected with an empty vector or a
 542 myc tagged POT1 expression vector. Forty-eight hours later cells were processed for IF-FISH.
 543 Telomeres were labels in cyan, POT1 in green and IE2 in red. Examples of POT1 localizing at telomeres
 544 (dashed squares) in uninfected cells are shown in the top row. Examples of IE2 colocalizing with POT1
 545 and telomeres in infected cells are presented in the bottom row (dashed squares).

546

547 Figure 7. Binding of TRF2 to viral DNA during HHV-6A/B infection. A) Schematic representation of the
 548 HHV-6A/B genome. The DR6 probe used for hybridization is shown in red. Uninfected and HHV-6A-
 549 infected HSB-2 cells (B-C) or uninfected and HHV-6B-infected Molt3 cells (D-E) were analyzed for TRF2
 550 binding to viral DNA using ChIP. The input was hybridized with Alu probe to assess quantity of starting
 551 material. Anti-IgG (negative control) or TRF2 antibodies were used for immunoprecipitation. Eluted
 552 DNA was serially diluted and hybridized with ³²P-labeled telomeric (TTAGGG)₃ or HHV-6 (DR6) probes.
 553 After hybridization the membranes were washed and exposed to X-ray films. The quantity of TRF2
 554 bound to telomeric and viral DNA is measured relative to the input. Results are of 3 independent
 555 experiments.

556

557 Figure 8. IE2 localized to VRC in the absence of TRF2. U2OS cells were transduced with a lentiviral
 558 vector coding for a Dox inducible shRNA against TRF2. Transduced cells were selected with puromycin
 559 for a week. A) Half of the cultures was treated with Dox for seven days to induce TRF2 knockdown
 560 (KD), as determined by western blot. B) Control (-Dox) and TRF2 KD (+Dox) cells were infected with
 561 HHV-6A for 48h and processed for IF-FISH. Telomeres were labeled in cyan, TRF2 in green and IE2 in
 562 red. As show in the -Dox condition, TRF2 colocalized with IE2 as well as diffuse (dashed square) and

563 punctate (dashed circle) telomeric signals. In the +Dox condition, TRF2 KD was confirmed with IE2
 564 colocalizing with diffuse telomere signals (dashed squares). C) DDR at telomeres as a consequence of
 565 TRF2 knockdown. U2OS cells were treated or not with Dox and infected with HHV-6A as in figure 6B.
 566 Cells were then processed for IF-FISH. Telomeres were labeled in cyan, IE2 in red, 53BP1 (as marker
 567 of DDR) in green and nuclei in blue.

568

569 Figure 9. Knockdown of TRF2 does not affect HHV-6A/B replication. SUP-T1 cells were transduced
 570 with a lentiviral vector coding for a Dox inducible shRNA against TRF2. A) Transduced cells were
 571 selected with puromycin for two weeks. TRF2 knockdown (KD) was induced by adding Dox to the
 572 culture medium for three weeks and confirmed by western blot. B-C) Control (-Dox) and TRF2 KD
 573 (+Dox) SUP-T1 cells were infected with HHV-6A (B) or HHV-6B (C). Whole cell DNA was isolated at
 574 various time points and the relative number of HHV-6A/B genomes determined and normalized
 575 against cellular DNA.

576

577 Bibliography

- 578 1. Ablashi D, Agut H, Alvarez-Lafuente R, Clark DA, Dewhurst S, DiLuca D, Flamand L, Frenkel N,
579 Gallo R, Gompels UA, Hollsberg P, Jacobson S, Luppi M, Lusso P, Malnati M, Medveczky P, Mori
580 Y, Pellett PE, Pritchett JC, Yamanishi K, Yoshikawa T. 2014. Classification of HHV-6A and HHV-
581 6B as distinct viruses. *Arch Virol* 159:863-70.
- 582 2. Yamanishi K, Okuno T, Shiraki K, Takahashi M, Kondo T, Asano Y, Kurata T. 1988. Identification
583 of human herpesvirus-6 as a causal agent for exanthem subitum [see comments]. *Lancet*
584 1:1065-7.
- 585 3. Phan TL, Carlin K, Ljungman P, Politikos I, Boussiotis V, Boeckh M, Shaffer ML, Zerr DM. 2018.
586 Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft-versus-Host
587 Disease after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-
588 Analysis. *Biol Blood Marrow Transplant* doi:10.1016/j.bbmt.2018.04.021.
- 589 4. Wallaschek N, Sanyal A, Pirzer F, Gravel A, Mori Y, Flamand L, Kaufer BB. 2016. The Telomeric
590 Repeats of Human Herpesvirus 6A (HHV-6A) Are Required for Efficient Virus Integration. *PLoS*
591 *Pathog* 12:e1005666.
- 592 5. Collin V, Flamand L. 2017. HHV-6A/B Integration and the Pathogenesis Associated with the
593 Reactivation of Chromosomally Integrated HHV-6A/B. *Viruses* 9.
- 594 6. Kaufer BB, Flamand L. 2014. Chromosomally integrated HHV-6: impact on virus, cell and
595 organismal biology. *Curr Opin Virol* 9C:111-118.
- 596 7. Achour A, Malet I, Deback C, Bonnafous P, Boutolleau D, Gautheret-Dejean A, Agut H. 2009.
597 Length variability of telomeric repeat sequences of human herpesvirus 6 DNA. *J Virol Methods*
598 159:127-30.
- 599 8. Gompels UA, Macaulay HA. 1995. Characterization of human telomeric repeat sequences from
600 human herpesvirus 6 and relationship to replication. *J Gen Virol* 76:451-8.
- 601 9. Kishi M, Harada H, Takahashi M, Tanaka A, Hayashi M, Nonoyama M, Josephs SF, Buchbinder
602 A, Schachter F, Ablashi DV, et al. 1988. A repeat sequence, GGGTTA, is shared by DNA of
603 human herpesvirus 6 and Marek's disease virus. *J Virol* 62:4824-7.
- 604 10. Thomson BJ, Dewhurst S, Gray D. 1994. Structure and heterogeneity of the a sequences of
605 human herpesvirus 6 strain variants U1102 and Z29 and identification of human telomeric
606 repeat sequences at the genomic termini. *J Virol* 68:3007-14.
- 607 11. Arbuckle JH, Medveczky MM, Luka J, Hadley SH, Luegmayer A, Ablashi D, Lund TC, Tolar J, De
608 Meirleir K, Montoya JG, Komaroff AL, Ambros PF, Medveczky PG. 2010. The latent human
609 herpesvirus-6A genome specifically integrates in telomeres of human chromosomes in vivo
610 and in vitro. *Proc Natl Acad Sci U S A* 107:5563-8.
- 611 12. Daibata M, Taguchi T, Taguchi H, Miyoshi I. 1998. Integration of human herpesvirus 6 in a
612 Burkitt's lymphoma cell line. *British journal of haematology* 102:1307-13.
- 613 13. Nacheva EP, Ward KN, Brazma D, Virgili A, Howard J, Leong HN, Clark DA. 2008. Human
614 herpesvirus 6 integrates within telomeric regions as evidenced by five different chromosomal
615 sites. *J Med Virol* 80:1952-8.
- 616 14. Torelli G, Barozzi P, Marasca R, Cocconcelli P, Merelli E, Ceccherini-Nelli L, Ferrari S, Luppi M.
617 1995. Targeted integration of human herpesvirus 6 in the p arm of chromosome 17 of human
618 peripheral blood mononuclear cells in vivo. *J Med Virol* 46:178-88.
- 619 15. Pellett PE, Ablashi DV, Ambros PF, Agut H, Caserta MT, Descamps V, Flamand L, Gautheret-
620 Dejean A, Hall CB, Kamble RT, Kuehl U, Lassner D, Lautenschlager I, Loomis KS, Luppi M, Lusso
621 P, Medveczky PG, Montoya JG, Mori Y, Ogata M, Pritchett JC, Rogez S, Seto E, Ward KN,

Yoshikawa T, Razonable RR. 2012. Chromosomally integrated human herpesvirus 6: questions and answers. *Reviews in medical virology* 22:144-55.

16. Gravel A, Dubuc I, Morissette G, Sedlak RH, Jerome KR, Flamand L. 2015. Inherited chromosomally integrated human herpesvirus 6 as a predisposing risk factor for the development of angina pectoris. *Proc Natl Acad Sci U S A* 112:8058-63.

17. Wright WE, Tesmer VM, Huffman KE, Levene SD, Shay JW. 1997. Normal human chromosomes have long G-rich telomeric overhangs at one end. *Genes Dev* 11:2801-9.

18. Olovnikov AM. 1973. A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. *J Theor Biol* 41:181-90.

19. de Lange T. 2009. How telomeres solve the end-protection problem. *Science* 326:948-52.

20. Zhang J, Rane G, Dai X, Shanmugam MK, Arfuso F, Samy RP, Lai MK, Kappei D, Kumar AP, Sethi G. 2016. Ageing and the telomere connection: An intimate relationship with inflammation. *Ageing Res Rev* 25:55-69.

21. Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H, de Lange T. 1999. Mammalian telomeres end in a large duplex loop. *Cell* 97:503-14.

22. Billaud T, Brun C, Ancelin K, Koering CE, Laroche T, Gilson E. 1997. Telomeric localization of TRF2, a novel human telobox protein. *Nat Genet* 17:236-9.

23. Broccoli D, Smogorzewska A, Chong L, de Lange T. 1997. Human telomeres contain two distinct Myb-related proteins, TRF1 and TRF2. *Nat Genet* 17:231-5.

24. Zhong Z, Shiue L, Kaplan S, de Lange T. 1992. A mammalian factor that binds telomeric TTAGGG repeats in vitro. *Mol Cell Biol* 12:4834-43.

25. Karlseder J, Broccoli D, Dai Y, Hardy S, de Lange T. 1999. p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. *Science* 283:1321-5.

26. Denchi EL, de Lange T. 2007. Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. *Nature* 448:1068-71.

27. Wang RC, Smogorzewska A, de Lange T. 2004. Homologous recombination generates T-loop-sized deletions at human telomeres. *Cell* 119:355-68.

28. Baumann P, Cech TR. 2001. Pot1, the putative telomere end-binding protein in fission yeast and humans. *Science* 292:1171-5.

29. Lei M, Podell ER, Cech TR. 2004. Structure of human POT1 bound to telomeric single-stranded DNA provides a model for chromosome end-protection. *Nat Struct Mol Biol* 11:1223-9.

30. Loayza D, Parsons H, Donigian J, Hoke K, de Lange T. 2004. DNA binding features of human POT1: a nonamer 5'-TAGGGTTAG-3' minimal binding site, sequence specificity, and internal binding to multimeric sites. *J Biol Chem* 279:13241-8.

31. Deng Z, Kim ET, Vladimirova O, Dheekollu J, Wang Z, Newhart A, Liu D, Myers JL, Hensley SE, Moffat J, Janicki SM, Fraser NW, Knipe DM, Weitzman MD, Lieberman PM. 2014. HSV-1 remodels host telomeres to facilitate viral replication. *Cell Rep* 9:2263-78.

32. Knecht H, Mai S. 2017. LMP1 and Dynamic Progressive Telomere Dysfunction: A Major Culprit in EBV-Associated Hodgkin's Lymphoma. *Viruses* 9.

33. Lajoie V, Lemieux B, Sawan B, Lichtensztejn D, Lichtensztejn Z, Wellinger R, Mai S, Knecht H. 2015. LMP1 mediates multinuclearity through downregulation of shelterin proteins and formation of telomeric aggregates. *Blood* 125:2101-10.

34. Gravel A, Gosselin J, Flamand L. 2002. Human Herpesvirus 6 immediate-early 1 protein is a sumoylated nuclear phosphoprotein colocalizing with promyelocytic leukemia protein-associated nuclear bodies. *J Biol Chem* 277:19679-87.

- 668 35. Tomoiu A, Gravel A, Flamand L. 2006. Mapping of human herpesvirus 6 immediate-early 2
669 protein transactivation domains. *Virology* 354:91-102.
- 670 36. Zimmermann M, Kibe T, Kabir S, de Lange T. 2014. TRF1 negotiates TTAGGG repeat-associated
671 replication problems by recruiting the BLM helicase and the TPP1/POT1 repressor of ATR
672 signaling. *Genes Dev* 28:2477-91.
- 673 37. Loayza D, De Lange T. 2003. POT1 as a terminal transducer of TRF1 telomere length control.
674 *Nature* 423:1013-8.
- 675 38. Cesare AJ, Hayashi MT, Crabbe L, Karlseder J. 2013. The telomere deprotection response is
676 functionally distinct from the genomic DNA damage response. *Mol Cell* 51:141-55.
- 677 39. Hanish JP, Yanowitz JL, de Lange T. 1994. Stringent sequence requirements for the formation
678 of human telomeres. *Proc Natl Acad Sci U S A* 91:8861-5.
- 679 40. Herbig U, Jobling WA, Chen BP, Chen DJ, Sedivy JM. 2004. Telomere shortening triggers
680 senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not
681 p16(INK4a). *Mol Cell* 14:501-13.
- 682 41. Jaworska J, Gravel A, Fink K, Grandvaux N, Flamand L. 2007. Inhibition of transcription of the
683 beta interferon gene by the human herpesvirus 6 immediate-early 1 protein. *J Virol* 81:5737-
684 48.
- 685 42. Poncet D, Belleville A, t'kint de Roodenbeke C, Roborel de Climens A, Ben Simon E, Merle-Beral
686 H, Callet-Bauchu E, Salles G, Sabatier L, Delic J, Gilson E. 2008. Changes in the expression of
687 telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic
688 leukemia. *Blood* 111:2388-91.
- 689 43. Trempe F, Gravel A, Dubuc I, Wallaschek N, Collin V, Gilbert-Girard S, Morissette G, Kaufer BB,
690 Flamand L. 2015. Characterization of human herpesvirus 6A/B U94 as ATPase, helicase,
691 exonuclease and DNA-binding proteins. *Nucleic Acids Res* 43:6084-98.
- 692 44. Gravel A, Tomoiu A, Cloutier N, Gosselin J, Flamand L. 2003. Characterization of the
693 immediate-early 2 protein of human herpesvirus 6, a promiscuous transcriptional activator.
694 *Virology* 308:340-53.
- 695 45. Gravel A, Dubuc I, Wallaschek N, Gilbert-Girard S, Collin V, Hall-Sedlak R, Jerome KR, Mori Y,
696 Carbonneau J, Boivin G, Kaufer BB, Flamand L. 2017. Cell culture systems to study Human
697 Herpesvirus 6A/B Chromosomal Integration. *J Virol* doi:10.1128/JVI.00437-17:pii: JVI.00437-
698 17. doi: 10.1128/JVI.00437-17.
- 699 46. Agulnick AD, Thompson JR, Iyengar S, Pearson G, Ablashi D, Ricciardi RP. 1993. Identification of
700 a DNA-binding protein of human herpesvirus 6, a putative DNA polymerase stimulatory factor.
701 *J Gen Virol* 74 (Pt 6):1003-9.
- 702 47. Lin K, Ricciardi RP. 1998. The 41-kDa protein of human herpesvirus 6 specifically binds to viral
703 DNA polymerase and greatly increases DNA synthesis. *Virology* 250:210-9.
- 704 48. Watson JD. 1972. Origin of concatemeric T7 DNA. *Nat New Biol* 239:197-201.
- 705 49. Greider CW, Blackburn EH. 1989. A telomeric sequence in the RNA of Tetrahymena telomerase
706 required for telomere repeat synthesis. *Nature* 337:331-7.
- 707 50. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. 1995. Telomere elongation in immortal
708 human cells without detectable telomerase activity. *EMBO J* 14:4240-8.
- 709 51. Neumann AA, Watson CM, Noble JR, Pickett HA, Tam PP, Reddel RR. 2013. Alternative
710 lengthening of telomeres in normal mammalian somatic cells. *Genes Dev* 27:18-23.
- 711 52. Li JS, Miralles Fuste J, Simavorian T, Bartocci C, Tsai J, Karlseder J, Lazzerini Denchi E. 2017.
712 TZAP: A telomere-associated protein involved in telomere length control. *Science* 355:638-
713 641.

53. Nishimura M, Wang J, Wakata A, Sakamoto K, Mori Y. 2017. Crystal Structure of the DNA-Binding Domain of Human Herpesvirus 6A Immediate Early Protein 2. *J Virol* 91.
54. Bochkarev A, Bochkareva E, Frappier L, Edwards AM. 1998. The 2.2 Å structure of a permanganate-sensitive DNA site bound by the Epstein-Barr virus origin binding protein, EBNA1. *J Mol Biol* 284:1273-8.
55. Hellert J, Weidner-Glunde M, Krausze J, Lunsdorf H, Ritter C, Schulz TF, Luhrs T. 2015. The 3D structure of Kaposi sarcoma herpesvirus LANA C-terminal domain bound to DNA. *Proc Natl Acad Sci U S A* 112:6694-9.
56. Deng Z, Lezina L, Chen CJ, Shtivelband S, So W, Lieberman PM. 2002. Telomeric proteins regulate episomal maintenance of Epstein-Barr virus origin of plasmid replication. *Molecular cell* 9:493-503.
57. Atanasiu C, Deng Z, Wiedmer A, Norseen J, Lieberman PM. 2006. ORC binding to TRF2 stimulates OriP replication. *EMBO Rep* 7:716-21.
58. Deng Z, Atanasiu C, Burg JS, Broccoli D, Lieberman PM. 2003. Telomere repeat binding factors TRF1, TRF2, and hRAP1 modulate replication of Epstein-Barr virus OriP. *J Virol* 77:11992-2001.
59. Hu J, Liu E, Renne R. 2009. Involvement of SSRP1 in latent replication of Kaposi's sarcoma-associated herpesvirus. *J Virol* 83:11051-63.
60. Weitzman MD, Lilley CE, Chaurushiya MS. 2010. Genomes in conflict: maintaining genome integrity during virus infection. *Annu Rev Microbiol* 64:61-81.
61. Kudoh A, Iwahori S, Sato Y, Nakayama S, Isomura H, Murata T, Tsurumi T. 2009. Homologous recombinational repair factors are recruited and loaded onto the viral DNA genome in Epstein-Barr virus replication compartments. *J Virol* 83:6641-51.
62. Daya S, Cortez N, Berns KI. 2009. Adeno-associated virus site-specific integration is mediated by proteins of the nonhomologous end-joining pathway. *J Virol* 83:11655-64.
63. Huang Y, Hidalgo-Bravo A, Zhang E, Cotton VE, Mendez-Bermudez A, Wig G, Medina-Calzada Z, Neumann R, Jeffreys AJ, Winney B, Wilson JF, Clark DA, Dyer MJ, Royle NJ. 2014. Human telomeres that carry an integrated copy of human herpesvirus 6 are often short and unstable, facilitating release of the viral genome from the chromosome. *Nucleic Acids Res* 42:315-27.
64. Ohye T, Inagaki H, Ihira M, Higashimoto Y, Kato K, Oikawa J, Yagasaki H, Niizuma T, Takahashi Y, Kojima S, Yoshikawa T, Kurahashi H. 2014. Dual roles for the telomeric repeats in chromosomally integrated human herpesvirus-6. *Sci Rep* 4:4559.

Figure 1

Figure 2

HHV-6A

HHV-6B

● Mock
● HHV-6-infected

Figure 3

Figure 4

Figure 5

Figure 6

U2OS

A

B

U2OS

C

D

Figure 6

Figure 7

Figure 8

Figure 9

Dox for 20 days then infection